Folates play a key role in one-carbon metabolism essential for the biosynthesis of purines,
thymidylate and hence DNA replication. The antifolate methotrexate has been rationally …

Although contemporary treatments cure more than 80% of children with acute lymphoblastic
leukaemia (ALL), some patients require intensive treatment and many patients still develop …

Purpose Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's
lymphoma with no accepted standard of care. This study evaluated the efficacy and …

Background Peripheral T-cell lymphoma unspecified (PTCLU) and mycosis fungoides (MF)
often show resistance to conventional chemotherapy. Gemcitabine should be considered a …

Purpose To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in
patients with lymphoma. Patients and Methods Pralatrexate, initially given at a dose of 135 …

Physical oncology has the potential to revolutionize cancer research and treatment. The
fundamental rationale behind this approach is that physical processes, such as transport …

T‐cell lymphomas (TCL) are aggressive lymphomas usually treated with CHOP
(cyclophsophamide, doxorubicin, vincristine, prednisolone)‐like regimens upfront. Recent …

Abstract Purpose: Pralatrexate (10-propargyl-10-deazaaminopterin) is an antifolate with
improved cellular uptake and retention due to greater affinity for the reduced folate carrier …

Purpose: T-cell lymphomas (TCL) are aggressive diseases, which carry a poor prognosis.
The emergence of new drugs for TCL has created a need to survey these agents in a rapid …

Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or
refractory peripheral T‐cell lymphoma. To assess its safety, efficacy, and pharmacokinetics …